
    
      The study will consist of one dose esclation part with a total of 3 dose levels. The Subjects
      will be randomized to receive SHR-1703 as reflected by the guiding principle for the dose
      esclation/expansion phase. Each dose group includes a screening period, a baseline period, an
      observational period, and a safety follow-up period.
    
  